Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN SULFATE versus NETROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN SULFATE versus NETROMYCIN.
NEOMYCIN SULFATE vs NETROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death by disrupting the cytoplasmic membrane.
Netromycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in bacteria.
1-2 g orally 4 times daily (8-16 g/day) for hepatic encephalopathy or intraluminal infection; 0.5-1 g orally 4 times daily for preoperative bowel preparation.
4-6 mg/kg IV once daily for serious infections; 1.5-2 mg/kg IV every 8 hours for gram-negative infections. Administered as intravenous infusion over 30-60 minutes.
None Documented
None Documented
2-3 hours (normal renal function); prolonged to 20-60 hours in anuria
Terminal elimination half-life is 2-3 hours in adults with normal renal function, but may extend to 24-48 hours in patients with impaired renal function.
Renal (glomerular filtration) >90% unchanged; small amount biliary/fecal (<3%)
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration; biliary/fecal elimination is minimal (<5%).
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic